GLP-1 Agonists and SGLT2 Inhibitors Have a Role in HF Treatment?

The management of patients with heart failure (HF) has taken an interesting and exciting turn thanks to studies demonstrating the positive effects and growing utilization of newer glucose-lowering therapies for reduction of HF outcomes — namely glucagon-like peptide 1 (GLP-1) agonists and oral sodium glucose cotransport 2 (SGLT2) inhibitors. These findings have led to a “crossover” effect among specialties wherein many HF specialists now consider themselves essential members of the healthcare team for patients with type 2 diabetes (T2D); likewise, many endocrinologists and nephrologists consider themselves integral to the care team of their patients with HF.

Many questions remain unanswered, however, regarding the therapeutic effects of GLP-1 agonists and SGLT2 inhibitors in HF. Here’s an overview of what we’ve learned so far about the potentially beneficial role of these therapies in treating patients with HF.

Click here to continue reading:

Παλαιότερα άρθρα